RxDoctor Payments Data

Judith Hernandez, MD

Nephrology · Live Oak, TXNPI 1124284757

Payments from drug & device makers

$1,627in general payments, 2019–2025

Across 67 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • OPKO Pharmaceuticals, LLC$330
  • AstraZeneca$237
  • Bayer$215
  • Amgen$190
  • Novartis$173
  • Akebia Therapeutics Inc$123
  • plus $359 from 10 others

What the payments were for

  • Food & beverage$1,58297%
  • Education$443%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,627 in reported general payments places this provider in the 45th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$300,975
Medicare patients
457
Services billed
3,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide21$57,876
AuryxiaFerric Citrate18$34,679
Sevelamer Carbonate88$19,090
LokelmaSodium Zirconium Cyclosilicate34$18,606
FarxigaDapagliflozin Propanediol17$14,490
Calcitriol175$2,484
Nifedipine ErNifedipine69$1,756
Potassium Chloride39$1,124
Hydralazine Hcl109$1,017
Losartan Potassium126$856
Bumetanide29$716
Furosemide100$506
Carvedilol45$446
Amlodipine Besylate84$404
Midodrine Hcl26$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$87$57,87621 claims
Akebia Therapeutics IncAuryxia$123$34,67918 claims
AstraZenecaLokelma, Farxiga$237$33,09651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Live Oak

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →